2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
19
Neoplasms
11
Polycystic Ovary Syndrome
9
Neoplasm Metastasis
4
Multiple Myeloma
4
Melanoma
4
Vomiting
3
Prostatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Leiomyoma
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Skin Neoplasms
2
Sarcoma
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Peripheral Nervous System Diseases
2
Ovarian Neoplasms
2
Obesity
2
Nausea
2
Myofibroma
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, B-Cell
2
Leukemia
2
Insulin Resistance
2
Inflammation
2
Infertility, Female
2
Interventions
Doxorubicin
17
Cyclophosphamide
15
Ifosfamide
11
fludarabine
8
Radiotherapy
8
tazemetostat
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
pegfilgrastim
3
cixutumumab
3
Trabectedin
3
Radiation
3
Imatinib Mesylate
3
Filgrastim
3
Docetaxel
3
Dacarbazine
3
sargramostim
2
liposomal doxorubicin
2
fludarabine phosphate
2
brostallicin
2
aldesleukin
2
X-Rays
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Radiation Dose Hypofractionation
2
Quality of Life
2
Nivolumab
2
Molecular Diagnostic Techniques
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Synovial
×
Tablets
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled